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Background and Aim 
Malnutrition is common in patients with alcohol-related liver disease and is associated with 
outcome in patients with alcoholic hepatitis. Trace elements (cobalt, copper, iron, selenium 
and zinc) are micronutrients essential for many cellular processes including antioxidant 
pathways. The prevalence and relevance of trace element deficiency is unknown in alcoholic 
hepatitis. We aimed to determine prevalence of trace element deficiency and their 
association with clinical outcomes in patients with alcoholic hepatitis. 
 
Methods 
Serum was obtained from patients with alcoholic hepatitis, alcohol-related cirrhosis and 
healthy volunteers as part of clinical trials, cohort studies and a biobank. Trace element 
concentration was measured by inductively-coupled plasma mass spectrometry. Association 
of trace element levels with development of infection within 90 days and mortality within 
28 and 90 days was evaluated by multivariate logistic regression. 
 
Results 
Serum from 302 patients with alcoholic hepatitis, 46 with alcohol-related cirrhosis and 15 
healthy controls was analysed for trace element concentration. The prevalence of zinc and 
selenium deficiency in alcoholic hepatitis was significantly higher than in alcohol-related 
cirrhosis at 85% and 67%, respectively. Zinc, selenium, copper and chromium were 
significantly different between groups. Iron was a predictor of development of infection 





Trace element deficiency in patients with alcoholic hepatitis is highly prevalent and 
associated with infection and mortality. Supplementation with selected trace elements may 
improve clinical outcomes in this patient group but further insight is required of their 
biological and clinical effects. 
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Trace elements are mineral elements present in small quantities in the human body. These 
include cobalt (Co), copper (Cu), iron (Fe), selenium (Se) and zinc (Zn) which are essential for 
a number of physiological, cellular and immune functions. Healthy dietary requirement has 
been studied and daily intake recommended by the World Health Organisation. 1 
 
Copper, selenium and zinc are particularly important as they are required in the synthesis of 
antioxidant enzymes such as catalase, superoxide dismutase and glutathione peroxidase, 
which are impaired in chronic liver disease and may contribute to its progression.2 
Additionally, these elements undergo biliary excretion, which is altered in liver disease. 
Copper also plays a role in haemoglobin formation, thyroid hormone production and myelin 
production.3 However, a pro-oxidant role has also been described.4 Chromium (Cr), although 
no longer considered an essential element, is involved in redox reactions in cells and in 
carbohydrate and lipid metabolism.5 
 
Malnutrition is common in patients with chronic liver disease6,7 and has a negative impact 
on their health related quality of life.7 Malnutrition has been best studied in patients with 
alcoholic hepatitis (AH), a serious complication of alcohol-related liver disease (ALD). 
Malnutrition in AH is almost universal and severity of malnutrition correlates with severity 
of AH.8 Intervention to increase calorie intake is effective in improving survival in this group 
of patients.9,10 However, trace element deficiency is a component of malnutrition that has 




Reduced serum levels of trace elements are present in patients with a range of chronic liver 
diseases11,12 and correlate with severity.12-14 Causes of deficiency are multifactorial but 
mainly due to reduced dietary intake and altered gut absorption. Zinc and selenium are the 
trace elements most studied in the context of liver disease. Zinc deficiency is associated with 
severity and prognosis in chronic liver disease.15 Selenium deficiency in chronic liver disease 
has also been reported in a number of studies but has not been associated with clinical 
outcomes.14,16,17 
 
The aim of this study was to determine whether there were trace element deficiencies in 
patients with AH compared to those with ALD cirrhosis and healthy controls and whether 






Written informed consent was obtained from all participants. Serum samples were obtained 
from five sources as described in detail below. (1) A prospective cohort study in Plymouth; 
(2) the Steroids or Pentoxifylline for Alcoholic Hepatitis (STOPAH) clinical trial; (3) the 
Imperial College Healthcare NHS Trust Tissue Bank; (4) the mechanism of action of N-
Acetylcysteine for reducing risk of infection in Alcoholic Hepatitis (NACAH) clinical trial; (5) 




Patients with severe AH or ALD cirrhosis were prospectively recruited to an observational 
cohort study conducted in University Hospitals Plymouth NHS Trust under NHS Health 
Research Authority (HRA) approval (15/LO/1501). Severe AH was defined according to the 
criteria applied to the STOPAH RCT: new onset jaundice within 3 months, bilirubin > 80 
µmol/L, coagulopathy, heavy alcohol use (> 80 g ethanol/day in males and > 60 g 
ethanol/day in females within the preceding 4 weeks), discriminant function (DF) ≥ 32.18 ALD 
was defined as similar alcohol consumption as the AH group but without jaundice and with 
established cirrhosis based on imaging, biopsy or transient elastography (stiffness > 20 kPa). 
Blood was taken by standard venepuncture into a serum separating tube within 72 hours of 
presentation prior to commencement of corticosteroids. Serum was obtained by 
centrifugation after standing for 20-30 minutes and stored in aliquots at -80°C. Patients with 
severe AH were treated with prednisolone 40 mg daily in the absence of active infection, 
hepatorenal syndrome or active gastrointestinal bleeding. Baseline biochemistry including 
DF and Model of End-stage Liver Disease (MELD) scores were recorded. Development of 
infection within 90 days of recruitment was prospectively recorded. Outcome at day 28 and 
day 90 was determined. 
 
Serum was obtained from patients recruited to the STOPAH randomised controlled trial 
(NHS HRA reference: 09/MRE09/59). Participant selection criteria and trial methodology has 
previously been described in detail.19 Serum from 192 participants were selected based on 
sample availability for trace element analysis.  
 
Serum samples were obtained from patients with ALD cirrhosis from Imperial College 
Healthcare NHS Trust Tissue Bank under HRA approval. Samples were provided fully 
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anonymised with alcohol consumption data but no further demographic or clinical 
information. 
 
Serum samples collected from participants recruited to the NACAH study (HRA reference: 
15/LO/0153) were also analysed. Peripheral blood samples were taken directly into serum 
saving tubes, which were kept at room temperature up to 20-30 minutes prior to 
centrifugation. Serum was stored at -80°C until thawing for trace element analysis. NACAH 
participant selection criteria were the same as the STOPAH trial. Participants were treated 
with prednisolone 40 mg daily for 28 days with or without NAC for 5 days. 
 
Healthy volunteer (HV) samples were obtained from laboratory and healthcare workers in 
University Hospitals Plymouth NHS Trust under HRA approval (South West – Cornwall and 
Plymouth reference: 1703). Written informed consent was taken and volunteers provided a 
self-declaration that they did not have any known acute or chronic health condition and 
consumed alcohol within UK government recommended guidelines (less than 112 g ethanol 
per week). Serum was taken and stored in aliquots as described above. 
 
Inductively coupled plasma mass spectrometry 
Serum samples were analysed for their Co, Cr, Cu, Fe, Se and Zn content immediately on 
receipt at the Analytical Research Facility, University of Plymouth using inductively coupled 
plasma mass spectrometry (ICP-MS). All laboratory ware was cleaned by soaking in 10% 
nitric acid for at least 24 hours before use followed by rinsing in copious amounts of high 
purity water (18 MΩ cm, Elga, High Wycombe, UK). Prior to analysis all serum samples were 
diluted fifty-fold into 2% nitric acid. Multi-element calibration standards were prepared 
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from elemental stock solutions (10,000, mg L-1, SCP Science, QMX Laboratories, Thaxted, 
UK) to cover the expected range of each analyte in the serum samples. The ICP-MS 
instrument, an iCAP RQ (Thermo Fisher Scientific, Hemel Hempstead, UK) was tuned and 
checked for conformance to the manufacturer’s specifications daily before use. The 
instrument was operated in collision cell mode, with helium as the cell gas, to negate the 
effect of any polyatomic interferences formed in the plasma or interface regions of the 
instrument. Indium and iridium were added, to give a final concentration of 10 µg/L, to all 
samples and calibration standards for use as internal standards to monitor for instrumental 
drift and sample matrix effects. All analyses were conducted under the ISO 9001:2015 
certification held by the Analytical Research Facility and all balances and pipettes used were 
checked for accuracy of operation daily before use. Quality assurance was provided for by 
the analysis of Seronorm (Billingstad, Norway) L1 and L2 trace elements in serum reference 
materials, which were prepared daily before use according to the manufacturer’s 
instructions. The found concentrations for all analytes were within the certified ranges for 
each Seronorm reference material. 
 
Statistical analysis 
Trace element concentration was described by mean and standard deviation. Mean trace 
element concentrations between sample categories (AH, ALD and HV) were compared by 
one-way ANOVA. Multiple comparisons between groups for each trace element were 
performed using t-tests with Bonferroni correction.  
 
For AH cases only, a stepwise logistic regression was performed including in the model trace 
elements and MELD where variables with univariate logistic regression of p < 0.25 were 
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included in the multivariate model. Multicollinearity was checked using variance inflation 
factor. Model goodness-of-fit was checked using Hosmer and Lemeshow test. Models were 
fitted for the dependent variable of presence or absence of infection within 90 days, death 
within 28 days and death within 90 days.  All analysis was performed using SPSS version 24 





Serum was analysed from 302 patients with severe AH (60% male, mean age 49, mean 
MELD 22.8), 43 patients with ALD cirrhosis (55% male, mean age 54, mean MELD 13.3) and 
15 HVs (61% male, mean age 31; table 1). Of those with ALD cirrhosis, 18 were actively 
consuming alcohol at potentially harmful levels (> 112 g [14 units] ethanol per week), 3 at 
low levels (< 112 g/week) and 22 were abstinent. 
 
Serum trace element deficiency is highly prevalent in patients with AH and ALD 
85% AH patients compared to 72% ALD patients had zinc deficiency (p=0.046) and 67% AH 
compared to 37% ALD patients were selenium deficient (p<0.001; table 2). Prevalence of 
copper and iron deficiency was similar in patients with AH and ALD (table 2). There is no 
established normal range for chromium or cobalt.  
 
We note that zinc is bound to albumin in the circulation and hypoalbuminaeamia may result 
in a falsely low serum zinc level.20 However, in patients with AH and ALD, serum zinc did not 
correlate with serum albumin (rho = 0.06; p=0.36). Additionally, diuretics and intravenous 
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human albumin solution (HAS) can alter serum levels of zinc and other trace elements.21 At 
the time of the baseline sample, 29% and 16% of the 192 AH patients from the STOPAH 
cohort received diuretics or HAS, respectively, but neither was associated with differences in 
any serum trace element level. The presence of hepatic encephalopathy (26% of the 




Serum trace element concentration is lower in patients with AH or ALD than healthy 
volunteers 
Serum concentration of, chromium, copper, selenium and zinc were all significantly 
different (all p<0.001 except copper p=0.04) between patients with AH, ALD and healthy 
volunteers (Figure 1). There were no significant differences between groups in serum 
concentration of iron or cobalt.  
 
Serum trace elements are lower in patients with AH than ALD cirrhosis 
Patients with severe AH had significantly lower selenium (0.63 v 0.79 µmol/L; p<0.001), 
chromium (36.7 v 61.7 nmol/L; p<0.001) and copper (16.2 v 18.6 µmol/L; p=0.03) compared 
to patients with ALD cirrhosis. 
  
Active alcohol consumption does not explain differences in serum trace elements in 
patients with ALD cirrhosis 
To determine whether active alcohol consumption was related to serum trace element 
levels, a subgroup analysis of patients with ALD cirrhosis obtained from the Imperial biobank 
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was performed. There were no differences between trace element levels in patients who 
were actively consuming alcohol > 112 g/week (n=7) compared to those that consumed less 
than this (n=25) (supplementary table 1). There were similar findings if the three patients 
with low level alcohol consumption were changed to the “actively consuming alcohol” 
group. 
 
Subgroup analysis of all ALD patients showed that samples from patients hospitalised with a 
complication of their cirrhosis had lower levels of cobalt, copper and selenium than those 
obtained from the biobank, who were outpatients with clinically stable cirrhosis 
(supplementary table 2). 
 
Serum trace elements are associated with clinical outcomes 
In patients with AH, trace element concentrations were not significantly associated with 
disease severity measured by MELD and DF. Univariate analysis demonstrated that MELD, 
bilirubin, albumin and iron were significantly different between patients who developed 
infection within 90 days and those that didn’t (table 3). Multivariate analysis found that 
MELD and iron were independently associated with infection within 90 days. For every 1 
µmol/L increase in iron, the odds of infection reduced by 4.2% (95% confidence interval 0.9-
7.3%; p=0.02). Serum iron was not correlated with C-reactive protein (rho = -0.14; p=0.63) 
or total white blood cell count (rho = -0.24; p=0.16). 
 
MELD and bilirubin were significantly different between survivors and non-survivors at day 
28 and day 90. Multivariate analysis demonstrated that MELD and zinc were independent 
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predictors of 28-and 90-day mortality (table 4 and 5).  At day 90, for every 1 µmol/L 




Trace element deficiencies are highly prevalent in patients with ALD cirrhosis and even more 
so in patients with AH with the most striking deficiencies seen with zinc and selenium; 85% 
of AH patients were zinc deficient and 67% were selenium deficient. Furthermore, trace 
element deficiencies were associated with clinical outcomes. Deficiency in zinc was an 
independent predictor of 28- and 90-day mortality and iron was an independent predictor 
of infection within 90 days. Heavy alcohol consumption itself does not account for trace 
element deficiencies, which are likely to be multifactorial due to disease severity and 
nutritional status. 
 
Protein-calorie malnutrition is almost universal among AH patients and is already recognised 
as an important contributor to severity of AH.8 Indeed, calorie supplementation improves 
survival.9,10 In addition to protein-calorie malnutrition, our data demonstrate the 
importance of micronutrient deficiencies. The cause of such deficiencies is due not only to 
reduced dietary intake but also altered absorption, metabolism and excretion.21,22 
Therefore, although these data cannot determine whether trace element deficiencies are 
independent of overall nutritional status, they are likely to have additional clinical impact 




Trace elements are essential for a wide range of cellular and immune functions. 
Approximately 10% of proteins encoded by the entire human genome have the potential to 
bind zinc,23 thus influencing many cellular processes including proliferation, differentiation 
and apoptosis.24 Zinc is an essential cofactor for many enzyme systems including antioxidant 
enzymes such as catalase, superoxide dismutase and glutathione peroxidase.25 Superoxide 
dismutase is a particularly important antioxidant in ALD as alcohol metabolised to aldehyde 
can produce superoxide radicals. Additionally, zinc is involved in maintaining gut epithelial 
integrity and in wound healing.26 
 
Zinc deficiency has been documented in patients with chronic liver disease including those 
with ALD cirrhosis12,13,27 and correlates with stage of cirrhosis.12 Additionally, lower zinc 
levels are associated with heavier alcohol consumption and raised markers of liver 
inflammation in patients without known liver disease.28 However, zinc deficiency in AH has 
not been fully investigated. There has been a single report in a cohort of 6 patients with mild 
to moderate AH in which hepatic zinc content was reduced.29 Serum zinc levels in AH 
patients have not been previously reported. 
 
Zinc replacement in patients with chronic liver disease may restore antioxidant enzyme 
pathways to protect the liver from oxidative stress related damage.30 In endothelial cells, 
deficiency activates pro-inflammatory transcription factors Nuclear Factor kappa B (NF-κB) 
and activator protein-1 (AP-1) and downregulates the anti-inflammatory peroxisome 
proliferator-activated receptor (PPAR) pathway.31,32 These alterations are partially 
ameliorated by zinc supplementation.32 A clinical trial of zinc sulphate supplementation in 
patients with chronic ALD cirrhosis is ongoing (NCT02072746). Preliminary results show an 
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improvement in serological markers of liver inflammation.33 A trial of zinc sulphate with 
anakinra (interleukin-1 antagonist) and pentoxifylline versus corticosteroids alone for AH 
will soon report findings (NCT01809132). However, this study will not be able to determine 
the role of zinc alone on clinical outcome. Further studies are required to fully evaluate the 
role of zinc supplementation in altering immune function in patients with ALD and AH. 
 
Selenium is an essential cofactor in several antioxidant pathways and forms a number of 
redox enzymes such as glutathione peroxidase (a selenopeptide), which are important to 
protect against oxidative injury.14 Selenium deficiency in chronic liver disease has been 
reported in a number of studies13,16,17 and is associated with severity of cirrhosis.13 Our data 
confirm these previous findings of selenium deficiency in ALD cirrhosis and also add that 
deficiency is even more prevalent and severe in patients with AH. 
 
Reduced serum transferrin but not serum iron was identified as an independent predictor of 
mortality in over 800 patients from the STOPAH cohort.34 Negative correlations with 
inflammatory parameters suggested that reduced transferrin was a marker of hepatocellular 
stress rather than altered iron metabolism. In the present study, we are unable to 
determine how low serum iron influences infection, but it was not correlated with markers 
of inflammation. Iron is involved in a number of biochemical pathways including oxygen 
transport. The majority of iron in the body is stored in erythrocytes in the form of heme but 
is present in hepatocytes and macrophages within ferritin, a storage protein.35 The toxic 
effects of iron overload to human tissues are well established due to its ability to generate 
oxygen free radicals. However, iron has bactericidal properties through the action of two 
metalloproteins, lactoferrin and neutrophil gelatinase-associated lipocalin (NGAL).36,37 
15 
 
Lactoferrin interacts directly with bacteria causing cell death while NGAL inhibits bacterial 
iron uptake, a critical factor for bacterial proliferation. This bactericidal role may explain 
why iron is an independent predictor of development of infection in patients with AH.  
 
Given the deficiencies in trace elements and their potential role in contributing to the 
damaging inflammatory response and perturbed immune function found in AH, there is a 
rationale to replace these to test whether there is a clinical benefit. Two clinical trials of 
trace element supplementation for AH have been performed. In one, 56 patients with 
severe AH were randomised to treatment with placebo or supplementation with an 
antioxidant cocktail including selenium and zinc.38 Those with active treatment had an 
improvement in bilirubin and reduced mortality at 28 days compared to the placebo group. 
The second trial randomised 70 patients with severe AH to an antioxidant cocktail and N-
acetylcysteine or corticosteroids and failed to demonstrate a survival difference at 6 
months.39 Both trials included other intervention in addition to trace elements making it 
different to determine the specific effects of the trace elements themselves. Further studies 
to investigate the biological and clinical effects of zinc and selenium supplementation in AH 
are warranted. 
 
In conclusion, trace element deficiency is highly prevalent among patients with ALD and AH. 
In those with severe AH, zinc and iron levels are independent predictors of survival and 
infection, respectively. These observations need further exploration to determine the 
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Table 1. Characteristics of AH, ALD and HV cohorts. *ALD patient characteristics were only 
available for the Plymouth cohort as the remaining samples were provided fully anonymised 
from a biobank. +BMI data only available for STOPAH cohort of AH patients. DF: Discriminant 








Age 49.3 (10.4) 53.7 (11.6) 31.4 (8.6) 
Gender (% male) 60% 55% 61% 
DF 67.7 (28.5) 38.6 (12.5) n/a 
MELD 22.8 (6.8) 13.3 (3.5) n/a 
Albumin (g/L) 25.8 (6.6) 29.0 (5.4) n/a 
Bilirubin (µmol/L) 320.2 (157.8) 71.0 (49.8) n/a 
BMI (kg/m2)+ 28.3 (6.0) n/a n/a 
Presence of hepatic 
encephalopathy 
26% 18% n/a 
 
 
Table 2. Published normal ranges for trace elements and mean (SD) serum concentration in 
AH, ALD and HVs. Prevalence of deficiency is defined as the percentage of individuals with 
trace element concentration below the published normal ranges. There is no agreed serum 
reference value for chromium and cobalt. *Based on values from the American Medical 


















































Se* 0.7-3.0 0.6 (0.3) 67 0.8 (0.4) 37 1.3 (0.2) 0 
Zn* 11.5-18.5 8.3 (3.4) 85 9.0 (3.1) 72 17.6 (4.5) 0 
 
Table 3. Multivariate logistic regression model for development of infection at within 90 




SE Wald p value Odds ratio 
95% confidence 
interval 
MELD 0.74 0.02 11.7 0.001 7.7 3.2-12.3 
Fe -0.43 0.02 6.2 0.013 4.2 0.9-7.3 
Constant -1.71 0.62 7.7 0.005     
 
 




SE Wald p value Odds ratio 
95% confidence 
interval 
MELD 0.12 0.03 22.4 <0.001 12.4 7.1-17.9 
Zn -0.11 0.06 3.9 0.047 10.6 0-20.0 
Constant -3.13 0.71 19.5 <0.001     
 
 




SE Wald p value Odds ratio 
95% confidence 
interval 
MELD 0.08 0.03 8.8 0.003 8.4 2.8-14.3 
Zn -0.15 0.06 6.3 0.012 14.0 3.3-23.5 










Figure 1. Serum trace element concentrations in patients with AH (n=302), ALD (n=43) and 
healthy volunteers (HV; n=15). ANOVA between all groups and comparisons between 
individual groups are shown. *p<0.05; **p<0.01; ***p<0.001. Co: cobalt; Cr: chromium; Cu: 
copper; Fe: iron; Se: selenium; Zn: zinc. 
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